eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2025-12-30 22 4 1685 1694 10.13005/bbra/3469 57360 article Sunil Kumar Chaitanya Padavala 1 Murugan Nithya 1 Naga Haritha Pamujlua 2 Sareesh Kankanala 1 Rajini Kolure 3 Department of Pharmaceutical Analysis, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, Telangana, India Department of Pharmaceutics, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, Telangana, India Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad, Telangana, India An effective reversed phase high performance liquid chromatographic approach has been developed and validated for the determined for Favipiravir and its impurities, which may coexist in bulk drugs and solid pharmaceutical dosage forms. Using a mobile phase of pH 5.8 phosphate buffer and methanol (Gradient Program) at a flow rate of 1 ml/min at a wavelength of 325 nm, the separation was accomplished by an Inspire column (3.0*150mm, 5µ).  Favipiravir recovery percentages at the three target concentrations were 99.67, 99.87, and 99.925, with a mean recovery of 99.59. The method's linearity varied from 0.1 to 0.5 PPM. This met the requirements for approval. The %RSD of 1.01, 0.63, and 0.95 for favipiravir, IMP-A, and IMP-B, respectively, showed how accurate the method was. The method's sensitivity is demonstrated by the LOD and LOQ values of 2.81 and 8.78, respectively.  The method was validated as per ICH guidelines to prove its worth in order to adopt by pharmaceutical industries as a part of their routine quality control analysis. https://www.biotech-asia.org/vol22no4/development-and-validation-of-a-rp-hplc-method-for-the-quantification-of-favipiravir-and-its-impurities-in-pharmaceutical-dosage-forms/ Favipiravir; ICH guidelines; Method development; RP-HPLC; Validation